Print Issue: February 01, 2007

Oral Platinum Analogue Looks Good

NEW YORK—Satraplatin, the first oral platinum analogue, is among the more promising second-line treatments for hormone-refractory prostate cancer (HRPC), a researcher said here at the 2006 Chemotherapy Foundation Symposium.

No Marker IDs Nonresponders to IV Iron

SAN DIEGO—No baseline transferrin saturation (TSAT), serum ferritin, or soluble transferrin receptor value predicts how hemodialysis patients with high ferritin levels will respond to IV iron therapy.

NO Higher in Proliferative Nephritis

Systemic nitric oxide (NO) levels are elevated in patients with proliferative lupus nephritis, researchers found. The association is independent of renal elimination of nitrate and nitrite (NOx), a measure of NO production.

Metabolic Syndrome and BPH

Prostate growth in men with benign prostatic hyperplasia (BPH) is increased in the presence of the metabolic syndrome, according to a study that supports a causative role for hyperinsulinemia.

Low-Carb Diets Do Not Increase CHD Risk

After decades of controversy, the verdict is in: Low-carbohydrate, higher-fat diets do not increase women’s risk of CHD. But the source of fat matters: It should be vegetable instead of animal.

Next post in News